897075--3/17/2008--REPROS_THERAPEUTICS

related topics

{product, candidate, development}

{property, intellectual, protect}

{product, liability, claim}

{personnel, key, retain}

{cost, contract, operation}

{product, market, service}

Because the data from our preclinical studies and early clinical trials for our product candidates are not necessarily predictive of future results, we can provide no assurances that any of them will have favorable results in clinical trials or receive regulatory approval. Delays in the commencement of preclinical studies and clinical trials testing of our current and potential product candidates could result in increased costs to us and delay our ability to generate revenues. Even if we successfully complete clinical trials for Proellex and Androxal, there are no assurances that we will be able to submit, or obtain FDA approval of, a new drug application. If we successfully develop products but those products do not achieve and maintain market acceptance, our business will not be profitable. Our product candidates have only been manufactured in small quantities to date, and we may face delays or complications in manufacturing quantities of our product candidates in sufficient quantities to meet the demands of late stage clinical trials and marketing. Our liability insurance may neither provide adequate coverage nor may it always be available on favorable terms or at all. We are thinly staffed and highly dependent on a limited number of management persons and key personnel, and if we lose these members of our team or are unable to attract and retain additional qualified personnel, our future growth and ability to compete would suffer. Risks Relating to Our Intellectual Property We face substantial uncertainty in our ability to protect our patents and proprietary technology.

Full 10-K form ▸

897075--3/17/2008--REPROS_THERAPEUTICS_INC.